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Purpose. The purpose of this study was to investigate the expression of cancer-associated fibroblast- (CAF-) related proteins and
the implications in breast phyllodes tumor (PT).Methods. Tissue microarrays of 194 PT cases (151 benign PT, 27 borderline PT, and
16 malignant PT) were constructed. We performed immunohistochemical staining for CAF-related proteins (podoplanin, prolyl
4-hydroxylase, FAP𝛼, S100A4, PDGFR 𝛼/𝛽, and NG2) and analyzed the results according to clinicopathologic parameters. Results.
Expression of PDGFR𝛼 and PDGFR𝛽 in the stromal component increased with increasing histologic grade of PT (𝑝 = 0.003 and
𝑝 = 0.034, resp.). Among clinicopathologic parameters, only expression of FAP𝛼 in stroma was associated with distant metastasis
(𝑝 = 0.002). In univariate analysis, stromal expression of PDGFR𝛼 was associated with shorter overall survival (𝑝 = 0.002). In Cox
multivariate analysis, stromal overgrowth and PDGFR𝛼 stromal positivity were associated with shorter overall survival (𝑝 = 0.006
and 𝑝 = 0.050, resp.). Furthermore, expression of PDGFR𝛽 in stroma was associated with shorter overall survival in patients
with malignant PT (𝑝 = 0.041). Conclusion. Stromal expression of PDGFR𝛼 and PDGFR𝛽 increased with increasing histologic
grade of PT. In addition, PDGFR stromal positivity was associated with shorter overall survival. These results suggest that CAFs
are associated with breast PT progression.
1. Introduction
Progress in cancer research has increasingly revealed the
clinical significance of the tumormicroenvironment. Among
various components of the tumormicroenvironment, cancer-
associated fibroblasts (CAFs), one of the most impor-
tant elements, have been widely studied [1]. CAFs are
located near the cancer cells and have been reported to be
involved in tumor initiation, tumor-stimulatory inflamma-
tion, metabolism, metastasis, drug response, and immune
surveillance [2]. Despite their significant effect on cancer
cells, the exact cell origin of CAFs is not completely under-
stood and there is even controversy concerning the definition
of CAF [1, 2]. Various proteins have been suggested as
markers for CAFs, including 𝛼-smooth muscle actin (SMA)
[3], tenascin-C [4], chondroitin sulfate proteoglycan (NG2)
[5], platelet-derived growth factor receptor (PDGFR)𝛼/𝛽 [6],
fibroblast activation protein (FAP) [7], podoplanin [8], prolyl
4-hydroxylase [9], and fibroblast-specific protein- (FSP-) 1
[5]. CAFs have been suggested to show various functional
subtypes that exhibit different characteristics [10], supporting
the hypothesis that CAFs have various phenotypes.
Phyllodes tumor (PT) is a relatively rare biphasic breast
tumor that accounts for only 0.3–1.5% of all breast tumors
[11]. It is composed of atypical spindle cell stroma and
usually benign epithelium [12]. Pathologically, differential
diagnosis is difficult because several histologic findings of
PT overlap with those of fibroadenoma, which is also a
fibroepithelial tumor, and PT shows heterogeneous histologic
features within the tumor [11, 13]. In addition, some cases
of PT show several clinical features of malignancy such as
relapse or distant metastasis [14].The histologic classification
of PT varies according to authors, but PT has been classified
as benign, borderline, and malignant according to the World
HealthOrganization classification of tumors of the breast [11].
A higher histologic grade of PT is associated with increased
risk of tumor recurrence or distant metastasis, indications
of tumor aggressiveness. Furthermore, among malignant PT,
9–36% of cases experience local recurrence, 9–40% of cases
progress with metastasis to the lungs, brain, or liver [15],
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Table 1: Source, clone, and dilution of antibodies used for immunohistochemical staining.
Antibody Company Clone Dilution
CAF phenotype-related proteins
Podoplanin Abcam, Cambridge, UK 18H5 1 : 100
Prolyl 4-hydroxylase Abcam, Cambridge, UK Polyclonal 1 : 200
FAP𝛼 Abcam, Cambridge, UK Polyclonal 1 : 100
S100A4 Abcam, Cambridge, UK Polyclonal 1 : 100
PDGFR𝛼 Abcam, Cambridge, UK Polyclonal 1 : 100
PDGFR𝛽 Abcam, Cambridge, UK Y92 1 : 100
NG2 Abcam, Cambridge, UK NG2 1 : 50
and some cases suffer death due to recurrence and distant
metastasis [16, 17]. The fibroblast is an important component
of PT [18, 19]; therefore, variations in tumor biology of
PT could be accounted for by the phenotype of associated
fibroblasts. However, the role of CAF-related proteins in
breast PT is poorly understood.The purpose of this study was
to investigate the expression of CAF-related proteins and its
implications in breast PT.
2. Materials and Methods
2.1. Patient Selection. Tissue samples from patients who were
diagnosed with breast PT from 2000 to 2010 in Severance
hospital were selected. All tissues were fixed in 10% buffered
formalin and embedded in paraffin. Archival hematoxylin
and eosin- (H&E-) stained slides for each case were reviewed
by a single pathologist (Ja Seung Koo). The PT histologic
grade was based on the World Health Organization classi-
fication of tumors of the breast [11]. The histologic grade
was evaluated with H&E-stained slides and clinical data
including patient age, recurrence, distant metastasis, and
patient survival were obtained by reviewing the patients’
medical records. The study was approved by the Institutional
Review Board of Yonsei University Severance Hospital.
2.2. Tissue Microarray. Construction of tissue microarray
was performed as previously described. Briefly, a representa-
tive area was selected on the H&E-stained slide of the tumor
and a corresponding spot was marked on the surface of the
paraffin block. Using a biopsy needle, the selected area was
punched out and the 5 mm tissue core was placed in a 5 ×
6 recipient block. To minimize extraction bias, we extracted
two tissue cores for every PT case. Finally, each separate tissue
core was assigned a unique tissue microarray location num-
ber linked to the database including other clinicopathologic
data and was used for immunohistochemical staining.
2.3. Immunohistochemistry. The antibodies used for immun-
ohistochemical staining in this study are shown in Table 1. All
immunostaining was performed using the constructed tissue
microarray. For immunohistochemistry, 5 𝜇m sections were
obtained with a microtome, transferred onto adhesive slides,
and dried at 62∘C for 30min. After incubation with primary
antibodies, immunodetection was performed with biotiny-
lated antimouse immunoglobulin followed by peroxidase-
labeled streptavidin using a labeled streptavidin biotin
kit with 3,3󸀠-diaminobenzidine chromogen as substrate.
For the negative control, the primary antibody incubation
step was omitted. Harris hematoxylin was used for tissue
counterstaining. All immunohistochemical markers were
assessed using light microscopy and evaluation of staining
was performed by calculating the proportion of stained cells
and immunostaining intensity. The proportion of stained
cells was defined as follows: 0, negative; 1, less than 30%
positive; and 2, more than 30% positive.The immunostaining
intensity was defined as follows: 0, negative; 1, weak; 2, mod-
erate; and 3, strong.The scores for proportion of stained cells
and immunostaining intensity were multiplied, and staining
was defined as positive when the final score was >1 [20].
2.4. Statistical Analysis. Data were analyzed using SPSS for
Windows, Version 21.0 (SPSS Inc., Chicago, IL, USA). Con-
tinuous variableswere compared using two-tailed Students’ 𝑡-
test and categorical data were compared using the Chi square
test. To evaluate the time to tumor recurrence and compare
the survivals between groups, Kaplan-Meier survival curves
and the log-rank test were used. Multivariate survival analy-
ses using a Cox’s proportional hazard model were performed
to characterize the prognostic factors in PT. A two-tailed 𝑝
value < 0.05 was considered statistically significant.
3. Results
3.1. Basal Characteristics of Phyllodes Tumors. This study
included 194 cases of breast PT, including 151 cases of benign
PT, 27 cases of borderline PT, and 16 cases of malignant PT.
The basal characteristics of the patients are shown in Table 2.
Greater patient age and larger tumor sizewere associatedwith
higher PT histologic grade (𝑝 = 0.017 and 𝑝 = 0.001, resp.).
Higher rate of tumor recurrence and distant metastasis were
also associated with higher PT histologic grade (𝑝 < 0.001).
Eight cases with distant metastasis showed lung metastasis.
3.2. Expression of CAF-Related Proteins according to Phyllodes
Tumor Histologic Grade. There were no significant differ-
ences in immunohistochemical staining in the epithelial
component according to PT histologic grade for any of the
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Table 2: Clinicopathologic characteristics of patients with phyllodes tumor.
Parameters Total 𝑛 = 196 (100%) PT, benign 𝑛 = 153(100%)
PT, borderline 𝑛 = 27
(100%)
PT, malignant 𝑛 = 16
(100%) 𝑝 value
Age (years, mean ± SD) 40.1 ± 12.3 38.9 ± 12.2 42.3 ± 11.5 47.6 ± 12.9 0.017
Tumor size (cm, mean ±
SD) 4.0 ± 2.6 3.6 ± 2.1 4.3 ± 2.5 6.7 ± 4.6 <0.001
Stromal cellularity <0.001
Mild 121 (61.7) 120 (78.4) 1 (3.7) 0 (0.0)
Moderate 63 (32.1) 33 (21.6) 23 (85.2) 7 (43.8)
Marked 12 (6.1) 0 (0.0) 3 (11.1) 9 (56.2)
Stromal atypia <0.001
Mild 156 (79.6) 151 (98.7) 5 (18.5) 0 (0.0)
Moderate 30 (15.3) 2 (1.3) 20 (74.1) 8 (50.0)
Marked 10 (5.1) 0 (0.0) 2 (7.4) 8 (50.0)
Stromal mitosis <0.001
0–4/10 HPFs 154 (78.6) 153 (100.0) 1 (3.7) 0 (0.0)
5–9/10 HPFs 31 (15.8) 0 (0.0) 26 (96.3) 5 (31.2)
≥10/10 HPFs 11 (5.6) 0 (0.0) 0 (0.0) 11 (68.8)
Stromal overgrowth <0.001
Absent 179 (91.3) 153 (100.0) 24 (88.9) 2 (12.5)
Present 17 (8.7) 0 (0.0) 3 (11.1) 14 (87.5)
Tumor margin <0.001
Circumscribed 176 (89.8) 150 (98.0) 20 (74.1) 6 (89.7)
Infiltrative 20 (10.2) 3 (2.0) 7 (25.9) 10 (62.5)
Tumor recurrence 18 (9.2) 5 (3.3) 6 (22.2) 7 (43.8) <0.001
Distant metastasis 8 (4.1) 0 (0.0) 1 (3.7) 7 (43.8) <0.001
PT, phyllodes tumor; HPF, high-power fields.
proteins analyzed (Table 3). For the stromal component,
the expression of PDGFR𝛼 and PDGFR𝛽 increased with
increasing PT histologic grade (𝑝 = 0.003 and 𝑝 = 0.034,
resp.) (Table 4 and Figure 1).
3.3. Correlation between the Expression of CAF-Related Pro-
teins in Phyllodes Tumor and Clinicopathologic Parameters.
We investigated the correlation between the expression of
CAF-related proteins in PT and clinicopathologic parame-
ters. Only expression of FAP𝛼 in the stromal cells was associ-
ated with distant metastasis (𝑝 = 0.002) (Figure 2). Other
clinicopathologic parameters, including age, tumor size,
stromal cellularity, stromal atypia, stromal mitosis, stromal
overgrowth, tumor margin, and tumor recurrence, were not
associated with the expression of CAF-related proteins in PT.
3.4. Impact of Expression of CAF-Related Proteins on Patient
Prognosis. Univariate analysis showed that stromal expres-
sion of PDGFR𝛼 was associated with shorter overall survival
(𝑝 = 0.002) (Table 5 and Figure 3(a)). Furthermore, in
Coxmultivariate analysis, higher PT histologic grade (hazard
ratio: 7.990, 95% CI: 2.196–29.07, and 𝑝 = 0.002) and stromal
overgrowth (hazard ratio: 7.288, 95% CI: 1.225–43.35, and
𝑝 = 0.029) were associated with shorter disease-free survival.
Regarding overall survival, stromal overgrowth (hazard ratio:
58.10, 95% CI: 3.116–1083, and 𝑝 = 0.006) and PDGFR𝛼
positivity (hazard ratio: 5.486, 95% CI: 1.003–30.01, and 𝑝 =
0.050) were associated with shorter overall survival (Table 6).
Furthermore, stromal expression of PDGFR𝛼 (𝑝 = 0.052)
(Figure 3(b)) and PDGFR𝛽 (𝑝 = 0.041) (Figure 3(c)) was
associated with shorter overall survival in malignant PT,
although statistical significance was not reached regarding
PDGFR𝛼 expression.
4. Discussion
In this study, we investigated the expression of CAF-related
proteins in breast PT according to histologic grade with the
aim of identifying a new therapeutic target for PT.
Recently, there have been many studies on the tumor
microenvironment as a novel therapeutic target. The tumor
microenvironment includes nontumor cells with nontrans-
formed elements, including immune system elements (such
as macrophages and lymphocytes), blood vessel cells, fibrob-
lasts, myofibroblasts, mesenchymal stem cells, adipocytes,
and extracellular matrix, in close proximity to tumor cells.
PT is a representative fibroepithelial tumor characterized
by fibrous stroma composed of fibroblasts surrounding the
epithelium. Previous studies reported that CD34-expressing
fibroblasts exist in mammary stroma. Because CD34-
expressing fibroblasts were observed in both fibroadenoma
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Table 3: Expression of CAF-related proteins in epithelial component of phyllodes tumor according to histologic grade∗.
Parameters Total 𝑛 = 179 (100%) PT, benign 𝑛 = 151(100%)
PT, borderline 𝑛 = 23
(100%)
PT, malignant 𝑛 = 5
(100%) 𝑝 value
Podoplanin 0.329
Negative 35 (19.6) 27 (17.9) 6 (26.1) 2 (40.0)
Positive 144 (80.4) 124 (82.1) 17 (73.9) 3 (60.0)
Prolyl 4-hydroxylase 0.621
Negative 174 (97.2) 146 (96.7) 23 (100.0) 5 (100.0)
Positive 5 (2.8) 5 (3.3) 0 (0.0) 0 (0.0)
FAP𝛼 0.794
Negative 166 (92.7) 140 (92.7) 21 (91.3) 5 (100.0)
Positive 13 (7.3) 11 (7.3) 2 (8.7) 0 (0.0)
S100A4 0.571
Negative 93 (52.0) 81 (53.6) 10 (43.5) 2 (40.0)
Positive 86 (48.0) 70 (46.4) 13 (56.5) 3 (60.0)
PDGFR𝛼 0.738
Negative 145 (81.0) 121 (80.1) 20 (87.0) 4 (80.0)
Positive 34 (19.0) 30 (19.9) 3 (13.0) 1 (20.0)
PDGFR𝛽 N/A
Negative 179 (100.0) 151 (100.0) 23 (100.0) 5 (100.0)
Positive 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
NG2 0.216
Negative 60 (33.5) 52 (34.4) 5 (21.7) 3 (60.0)
Positive 119 (66.5) 99 (65.6) 18 (78.3) 2 (40.0)
∗Seventeen tumors without an epithelial component were excluded.
PT, phyllodes tumor.
and PT [19], efficient treatment for fibroepithelial tumors
might be achieved by targeting the fibrous stroma. However,
there are no studies on the expression of CAF-related pro-
teins in PT, and as PT shows heterogeneous tumor stromal
features, the expression of CAF-related proteins is predicted
to vary in each type.
In this study, we performed immunohistochemical stain-
ing for CAF-related proteins focusing on the stromal com-
ponent. Our results showed that the expression of PDGFR𝛼
and PDGFR𝛽 increased with increasing PT histologic grade.
Platelet-derived growth factor is a major mitogen for several
cell types, including connective tissue cells, that is activated
by binding to two protein tyrosine kinase receptors (PDGFR𝛼
and PDGFR𝛽). PDGF signaling in tumor cells induces point
mutations, amplification, and translocations, which stimulate
autocrine stimulatory loops [6, 21]. For example, PDGFR𝛼
and 𝛽 are two well-known receptors that participate in breast
cancer progression [22]. In addition, in breast cancer, the
desmoplastic response appears to be mediated by PDGF-AA
signaling in PDGFR𝛼 type CAFs [23]. Desmoplasia refers to
the growth of fibrous or connective tissue near the tumor
and is increased in tumors with aggressive properties. The
results from our study revealed that higher grade PT with
more active fibroblasts showed higher expression of PDGFR𝛼
and 𝛽, suggesting that fibroblasts with a CAF phenotype are
associated with PT progression.
Stromal PDGFR𝛼 expression was related to the prognosis
of patients with PT. Furthermore, subgroup analysis in
malignant PT showed that stromal PDGFR𝛽 expression was
associated with shorter overall survival and, although statis-
tical significance was not noted, there was also a trend for
increased stromal PDGFR𝛼 expression. In previous studies of
glioma [24], squamous cell carcinoma of the head and neck
[25], colorectal cancer [26], pancreatic cancer [27], and T cell
lymphoma [28], PDGFR activation induced the intracellular
signaling pathway and promoted cell migration, invasion,
survival, and proliferation [29]. Similarly, PDGFR activation
is related to lymphatic metastasis in pancreatic cancer [30]
and gastric cancer [31], suggesting that PDGFR might be
used as a prognostic marker in malignant PT. This should be
validated in future studies.
We found that expression of FAP𝛼 in stroma was associ-
ated with distant metastasis. Fibroblast activation protein is
expressed by reactive CAFs in tumor stroma or granulation
tissue and is known to be involved in wound healing. The
expression of FAP in CAFs is reported in various carcinomas
and is used as an important marker of CAF [32, 33]. In a
meta-analysis that analyzed the clinical implication of FAP
overexpression in solid tumors of colorectal cancer, pan-
creatic adenocarcinoma, non-small cell lung cancer, breast
cancer, medullary thyroid carcinoma, and oral squamous cell
carcinoma, high FAP expression was related to the risk of
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Figure 1: Expression of CAF-related proteins according to the histologic grade of phyllodes tumor.The stromal expression of PDGFR𝛼 and 𝛽
increased with increasing phyllodes tumor histologic grade. The yellow circle indicates epithelium and the white circle indicates the stroma.
CAF, cancer-associated fibroblast; H&E, hematoxylin and eosin stain; FAP, fibroblast activation protein; PDGFR, platelet-derived growth
factor receptor; NG2, chondroitin sulfate proteoglycan.
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Table 4: Expression of CAF-related proteins in the stromal component of phyllodes tumor according to histologic grade.
Parameters Total 𝑛 = 196 (100%) PT, benign 𝑛 = 153(100%)
PT, borderline 𝑛 = 27
(100%)
PT, malignant 𝑛 = 16
(100%) 𝑝 value
Podoplanin 0.728
Negative 52 (26.5) 41 (26.8) 8 (29.6) 3 (18.8)
Positive 144 (73.5) 112 (73.2) 19 (70.4) 13 (81.2)
Prolyl 4-hydroxylase 0.563
Negative 192 (98.0) 149 (97.4) 27 (100.0) 16 (100.0)
Positive 4 (2.0) 4 (2.6) 0 (0.0) 0 (0.0)
FAP𝛼 0.105
Negative 188 (95.9) 149 (97.4) 25 (92.6) 14 (87.5)
Positive 8 (4.1) 4 (2.6) 2 (7.4) 2 (12.5)
S100A4 0.104
Negative 65 (33.2) 56 (36.6) 7 (25.9) 2 (12.5)
Positive 131 (66.8) 97 (63.4) 20 (74.1) 14 (87.5)
PDGFR𝛼 0.003
Negative 179 (91.3) 142 (92.8) 26 (96.3) 11 (68.8)
Positive 17 (8.7) 11 (7.2) 1 (3.7) 5 (31.2)
PDGFR𝛽 0.034
Negative 80 (40.8) 69 (45.1) 5 (18.5) 6 (37.5)
Positive 116 (59.2) 84 (54.9) 22 (81.5) 10 (62.5)
NG2 0.695
Negative 93 (47.4) 75 (49.0) 11 (40.7) 7 (43.8)
Positive 103 (52.6) 78 (51.0) 16 (59.3) 9 (56.2)
PT, phyllodes tumor.
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p = 0.002
Figure 2: Correlation between stromal expression of fibroblast
activation protein (FAP)𝛼 in phyllodes tumor anddistantmetastasis.
distant metastasis (OR: 2.56) [34], showing similar results to
our study. FAP regulates proteolysis of the extracellular cell
matrix in tumor stroma, causing stromal cell proliferation
and invasiveness. Therefore, it could be speculated that
tumors with high expression of FAP𝛼 are prone to metastasis
to distant organs [35, 36].
The clinical significance of this study is the role of CAFs
as a potential therapeutic target. Sunitinib, a US Food and
Drug Administration- (FDA-) approved PDGFR inhibitor, is
currently used in the treatment of advanced renal cell carci-
noma [37], advanced progressive pancreatic neuroendocrine
tumor [38], and advanced radioiodine refractory thyroid
carcinoma [39]. Furthermore, ongoing preclinical trials are
testing the therapeutic effect of another PDGFR inhibitor,
imatinib mesylate, in gastrointestinal stromal tumor [40, 41]
and in vitro and in vivo studies of malignant peripheral nerve
sheath tumors have shown promising results [42]. Therefore,
inhibition of PDGFR in PT might be a potential therapeutic
strategy. However, further investigation regarding the effect
of these inhibitors in PT is required.
Taken together, our data show that expression of
PDGFR𝛼 and PDGFR𝛽 in the stromal component increased
with increased PT histologic grade. Also, stromal expression
of PDGFR was associated with shorter overall survival.
Overall, the expression of CAF-related proteins is related to
the histologic grade of breast PT and PDGFR inhibitors in
particular have potential as novel treatments for PT.
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Table 5: Univariate analysis of the impact of CAF-related proteins in the stromal component of phyllodes tumor on patient prognosis using
the log-rank test.
Parameters Number of patientsTotal/recurrence/metastasis
Disease-free survival Overall survival
Median survival (95%
CI) months 𝑝 value
Median survival
(95% CI) months 𝑝 value
Podoplanin 0.936 0.494
Negative 52/5/3 160 (146–174) 166 (155–178)
Positive 144/13/5 166 (158–175) 177 (171–182)
Prolyl 4-hydroxylase n/a n/a
Negative 192/18/8 n/a n/a
Positive 4/0/0 n/a n/a
FAP𝛼 0.099 0.233
Negative 188/16/7 164 (157–171) 172 (167–177)
Positive 8/2/1 131 (71–191) 162 (123–200)
S100A4 0.607 0.792
Negative 65/5/3 163 (152–174) 168 (159–177)
Positive 131/13/5 165 (155–174) 176 (170–182)
PDGFR𝛼 0.698 0.002
Negative 179/16/5 167 (159–174) 177 (173–182)
Positive 17/2/3 121 (102–140) 113 (90–136)
PDGFR𝛽 0.394 0.087
Negative 80/6/1 164 (154–174) 174 (170–178)
Positive 116/12/7 163 (153–173) 172 (164–179)
NG2 0.830 0.216
Negative 93/8/2 145 (136–154) 155 (151–160)
Positive 103/10/6 165 (155–175) 172 (164–180)
Table 6: Multivariate analysis of disease-free and overall survival in patients with phyllodes tumors.
Included factor Disease-free survival Overall survival
Hazard ratio 95% CI 𝑝 value Hazard ratio 95% CI 𝑝 value
Histologic grade 0.002 N/A
Benign versus
borderline/malignant 7.990 2.196–29.07 N/A N/A
Stromal cellularity 0.597 0.467
Mild versus
moderate/marked 0.625 0.109–3.569 2.862 0.169–48.60
Stromal atypia 0.886 0.708
Mild versus
moderate/marked 0.881 0.158–4.925 0.630 0.056–7.049
Stromal mitosis 0.854 0.437
0–4/10 HPF versus
>4/10 HPF 0.782 0.057–10.81 0.210 0.004–10.70
Stromal overgrowth 0.029 0.006
Absent versus present 7.288 1.225–43.35 58.10 3.116–1083
Tumor margin 0.275 0.187
Circumscribed versus
infiltrative 0.468 0.120–1.830 0.321 0.060–1.732
PDGFR𝛼 (stromal) 0.867 0.050
Negative versus
positive 0.879 0.193–4.008 5.486 1.003–30.01
HPF, high-power field.
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Figure 3: Overall survival curves according to the status of CAF-related proteins in stromal component of phyllodes tumor. (a) Univariate
analysis showed that stromal expression of PDGFR𝛼 was associated with shorter overall survival in phyllodes tumor. (b) Stromal expression
of PDGFR𝛼 was associated with shorter overall survival in malignant phyllodes tumor, although statistical significance was not reached
regarding PDGFR𝛼 expression. (c) Stromal expression of PDGFR𝛽was associated with shorter overall survival inmalignant phyllodes tumor.
CAF, cancer-associated fibroblast; PDGFR, platelet-derived growth factor receptor.
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